Market volatility has dropped since the recent correction, but with plenty of items on the news front, we could see a volatility spike at any point.
Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.
Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook...
Barchart Research What to Expect from NVO Earnings NVO Generated August 4, 2026 Current Price $44.28 EPS Estimate $$0.81 Consensus Rating Hold Average Move 4.38% Novo Nordisk Reports Tomorrow With Injectable...
Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.
Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (July) ISM manufacturing ...
Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.
Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.
Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly's advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo's latest...
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END